HPRA investigating case of special interest
Speaking at the NPHET briefing, HRPA Chief Executive Dr Lorraine Nolan said the individual in question is making a recovery.
She said the case will receive utmost priority .
In a statement the HRPA said the report will be notified to the EU s safety database and will be considered in the context of continuous monitoring coordinated by the EMA.
Lorraine Nolan has said there has been one case reported to the HPRA relating to blood clotting.
She said it is not clear if it meets the profile of rare blood clotting events, but said the case will receive utmost priority | Live updates: https://t.co/3WgoocIrVupic.twitter.com/KrP8bmtBxw
Pressure grows on Government to review use of AstraZeneca vaccines irishtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from irishtimes.com Daily Mail and Mail on Sunday newspapers.
Irish medicines watchdog probing first blood clot case in AstraZeneca vaccine recipient
The HPRA confirmed it has received a case which describes “an unusual clot in the brain.” By Céimin Burke Thursday 8 Apr 2021, 6:07 PM 5 hours ago 25,049 Views 17 Comments
Image: PA
Image: PA
IRELAND’S MEDICINES REGULATOR is investigating the first potential case of a very rare blood clot in someone who received the AstraZeneca Covid-19 vaccine.
The Health Products Regulatory Authority (HPRA), confirmed it has received “a case of interest associated with the AstraZeneca vaccine, which describes cerebral venous sinus thrombosis (CVST), an unusual clot in the brain.”
The Irish Times reported this evening that the case involves a 40-year-old Dublin woman who is being treated for CVST at the Mater Hospital in Dublin.
Watchdog Examines First Irish Blood Clot Case fm104.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fm104.ie Daily Mail and Mail on Sunday newspapers.
The board of the Mater Hospital is made up of medical and non-medical members.
Sources have suggested members of the board who were not given the vaccine as part of their medical role should be offered the option of one because of their importance to the hospital.
Meanwhile, as of Saturday, the vaccination roll-out nationally had administered a first dose to 660,800 people, with 271,524 getting a second dose.
An evaluation of the association between rare blood clots and the Oxford AstraZeneca vaccine is due from the European Medicines Agency (EMA) this week.
Earlier yesterday, a senior official in the EMA said there was a link between the vaccine and very rare blood clots in the brain, but the possible causes were still unknown.